Clinical Trial Update: Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating renal effects of three iodinated contrast media in patients at risk undergoing coronary angiography has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Diabetes Mellitus
• Renal Impairment

Snippet

Sponsor: GE Healthcare | Conditions: Coronary Artery Disease (CAD), Renal Impairment | Phase 4 | Status: WITHDRAWN